1. Market Research
  2. > Norgine BV - Product Pipeline Review - 2013

Norgine BV - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 30 pages

Norgine BV - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Norgine BV - Product Pipeline Review - 2013” provides data on the Norgine BV’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Norgine BV’s corporate website, SEC filings, investor presentations and featured press releases, both from Norgine BV and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Norgine BV - Brief Norgine BV overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Norgine BV human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Norgine BV with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Norgine BV’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Norgine BV’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Norgine BV in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Norgine BV’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Norgine BV.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Norgine BV and identify potential opportunities in those areas.

Table Of Contents

Norgine BV - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Norgine BV Snapshot 5
Norgine BV Overview 5
Key Information 5
Key Facts 5
Norgine BV - Research and Development Overview 6
Key Therapeutic Areas 6
Norgine BV - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Norgine BV - Pipeline Products Glance 10
Norgine BV - Late Stage Pipeline 10
Registration Filed Products/Combination Treatment Modalities 10
Phase III Products/Combination Treatment Modalities 11
Norgine BV Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Norgine BV - Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Norgine BV - Drug Profiles 14
cetilistat 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
IBD Therapy 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
methoxamine 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
NPJ-5006 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
NRL-994 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Norgine BV - Pipeline Analysis 21
Norgine BV - Pipeline Products by Therapeutic Class 21
Norgine BV - Pipeline Products by Route of Administration 22
Norgine BV - Pipeline Products By Mechanism of Action 23
Norgine BV - Recent Pipeline Updates 24
Norgine BV - Dormant Projects 25
Norgine BV - Discontinued Pipeline Products 26
Discontinued Pipeline Product Profiles 26
ulimorelin hydrochloride 26
Norgine BV - Company Statement 27
Norgine BV - Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables


Norgine BV, Key Information 5
Norgine BV, Key Facts 5
Norgine BV - Pipeline by Indication, 2013 7
Norgine BV - Pipeline by Stage of Development, 2013 8
Norgine BV - Monotherapy Products in Pipeline, 2013 9
Norgine BV - Filed, 2013 10
Norgine BV - Phase III, 2013 11
Norgine BV - Phase II, 2013 12
Norgine BV - Pre-Clinical, 2013 13
Norgine BV - Pipeline By Therapeutic Class, 2013 21
Norgine BV - Pipeline By Route of Administration, 2013 22
Norgine BV - Pipeline Products By Mechanism of Action, 2013 23
Norgine BV - Recent Pipeline Updates, 2013 24
Norgine BV - Dormant Developmental Projects,2013 25
Norgine BV - Discontinued Pipeline Products, 2013 26

List of Figures


Norgine BV - Pipeline by Indication, 2013 7
Norgine BV - Pipeline by Stage of Development, 2013 8
Norgine BV - Monotherapy Products in Pipeline, 2013 9
Norgine BV - Pipeline By Therapeutic Class, 2013 21
Norgine BV - Pipeline By Route of Administration, 2013 22
Norgine BV - Pipeline Products By Mechanism of Action, 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.